Commitments and contingencies (Details Narrative) - USD ($) |
3 Months Ended | ||||
|---|---|---|---|---|---|
Aug. 27, 2021 |
Sep. 06, 2018 |
Mar. 17, 2017 |
Mar. 31, 2022 |
Jun. 30, 2020 |
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
| Law suit filing date | May 28, 2019 | ||||
| G Farma Labs Limited [Member] | |||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
| Sale leaseback transaction, net book value | $ 622,670 | ||||
| Loss contingency receivable, proceeds | $ 249,481 | ||||
| Notes Purchase Agreement [Member] | G Farma Labs Limited [Member] | |||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
| Purchase of secured promissory notes | $ 500,000 | ||||
| Increased aggregate principal face amount | 1,100,000 | ||||
| Debt instrument periodic payment | 10,239 | ||||
| Ballon payments on notes | $ 894,172 | ||||
| Equity Purchase and Issuance Agreement [Member] | G Farma Labs Limited [Member] | |||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
| Equal interest percentage | 3.75% | ||||
| Description of equity interests issuable to acquire the entity | On March 4, 2019, Addendum VIII increased the G Farma Equity Entities’ equity interest to which Mentor is immediately entitled to 3.843%, and added Goya Ventures, LLC as a G Farma Equity Entity | ||||
| Settlement Agreement And Mutual Release [Member] | G Farma [Member] | |||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
| Liability for Unpaid Claims and Claims Adjustment Expense Schedule, Discussion | The Settlement Agreement requires the G Farma Entities to pay the Company an aggregate of $ 500,000 plus interest, payable monthly as follows: (i) $500 per month for 12 months beginning on September 5, 2021, (ii) $1,000 per month for 12 months beginning September 5, 2022, (iii) $2,000 per month for 12 months beginning September 5, 2023, and (iv) increasing by an additional $1,000 per month on each succeeding September 5th thereafter, until the settlement amount and accrued unpaid interest is paid in full. Interest on the unpaid balance shall initially accrue at the rate of 4.25%, commencing February 25, 2021, and shall be adjusted on February 25th of each year to equal the Prime Rate as published in the Wall Street Journal plus 1%. | ||||
| Liability for unpaid claims and claims adjustment expense, net | $ 500,000 | ||||
| Liability for Unpaid Claims and Claims Adjustment Expense, Adjustments | $ 2,000,000 | ||||
| X | ||||||||||
- Definition Long term purchase commitment increased amount. No definition available.
|
| X | ||||||||||
- Definition Description of equity interests issued or issuable to acquire the entity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Percentage of voting equity interests acquired at the acquisition date in the business combination. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of the required periodic payments including both interest and principal payments. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt. No definition available.
|
| X | ||||||||||
- Definition Liability as of the balance sheet date for amounts representing estimated cost of settling unpaid claims under the terms of the underlying insurance policies, less estimated reinsurance recoveries on such claims. This includes an estimate for claims which have been incurred but not reported. Claim adjustment expenses represent the costs estimated to be incurred in the settlement of unpaid claims. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Sum of adjustments to the estimated reserve for unpaid claims and claims adjustment expense. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Discussion accompanying a schedule reflecting the financial activity during the period in the reserves for unpaid claims and claims adjustment expense. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The minimum amount the entity agreed to spend under the long-term purchase commitment. No definition available.
|
| X | ||||||||||
- Definition States the date the complaint was formally filed in a court of law, in arbitration or mediation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of cash inflow from the collection of receivables related to a loss contingency. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The net book value of the asset(s) sold in connection with the sale of the property to another party and lease back to the seller. Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|